Pfizer Inc submits new paediatric data for Lipitor to EMEA
PFE | Quote | Chart | News | PowerRating -- Health care company Pfizer Inc (NYSE:PFE) declared on Wednesday the
submission of paediatric data for Lipitor (atorvastatin) to the
European Medicines Agency (EMEA).
This follows the EMEA's conclusion that Pfizer's programme studying the
use of Lipitor in children with high cholesterol is in compliance with
its requirements.
Pfizer has also developed a new chewable form of Lipitor, including a
paediatric-appropriate 5 mg dose, which is part of this submission.
The company will be eligible and plans to apply for an additional six
months of patent/supplementary protection certificate protection for
Lipitor in certain European Union countries if it fulfils all further
requirements of the EU Paediatric Medicines Regulation.
According to Pfizer, approximately one in 500 people suffer from an
inherited disorder called Familial Hypercholesterolemia (FH) which
causes high levels of LDL-cholesterol ("bad" cholesterol) and an
increased risk of heart disease.
Comments on this story may be sent to admin@m2.com
For full details on Pfizer Inc (PFE) PFE. Pfizer Inc (PFE) has Short Term PowerRatings at TradingMarkets. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.
- Pfizer teams up to offer online health management - 02/09/10
- Atrium's role at Pfizer growing - 02/09/10
- BRIEF: Pfizer partners with interactive-technology firm to help boost health outcomes - 02/08/10
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness - 02/08/10
- BRIEF: Bristol-Myers freezing salaries - 02/06/10
- More News >>


